Detalhe da pesquisa
1.
Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Nature
; 558(7710): E1, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29769713
2.
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Nature
; 550(7674): 128-132, 2017 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28953875
3.
Quantitative ligand and receptor binding studies reveal the mechanism of interleukin-36 (IL-36) pathway activation.
J Biol Chem
; 293(2): 403-411, 2018 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29180446
4.
PULSE SPR: A High Throughput Method to Evaluate the Domain Stability of Antibodies.
Anal Chem
; 90(20): 12221-12229, 2018 10 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30209948
5.
An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy.
Nat Cancer
; 3(3): 337-354, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35256819
6.
VISTA is an activating receptor in human monocytes.
J Exp Med
; 218(8)2021 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34106206
7.
Discovery of a Potent and Selective Covalent p300/CBP Inhibitor.
ACS Med Chem Lett
; 12(5): 726-731, 2021 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34055218
8.
Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
Cancer Res
; 81(12): 3402-3414, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33687950
9.
Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity.
Mol Cancer Ther
; 19(4): 1040-1051, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31974274
10.
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.
Mol Cancer Res
; 17(2): 409-419, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30429212
11.
ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models.
Mol Cancer Ther
; 17(5): 1039-1050, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29592882
12.
Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.
J Med Chem
; 61(24): 11074-11100, 2018 12 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30384606
13.
Structure of the SH3 domain of human osteoclast-stimulating factor at atomic resolution.
Acta Crystallogr Sect F Struct Biol Cryst Commun
; 62(Pt 9): 844-8, 2006 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16946461
14.
Reversible amyloid formation by the p53 tetramerization domain and a cancer-associated mutant.
J Mol Biol
; 327(3): 699-709, 2003 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-12634062
15.
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Mol Cancer Res
; 13(11): 1465-77, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26217019
16.
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
Mol Cancer Ther
; 14(5): 1141-51, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25731184
17.
Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule.
MAbs
; 5(3): 358-63, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23549062
18.
Design and generation of DVD-Ig™ molecules for dual-specific targeting.
Methods Mol Biol
; 899: 145-56, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22735951
19.
Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design.
MAbs
; 3(5): 487-94, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21814039
20.
Purification, crystallization and preliminary X-ray analysis of Caenorhabditis elegans ubiquitin-conjugation enzyme M7.1.
Acta Crystallogr D Biol Crystallogr
; 59(Pt 3): 544-6, 2003 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-12595721